Skip to main content

Ingelvac PRRS MLV

This page contains information on Ingelvac PRRS MLV for veterinary use.
The information provided typically includes the following:
  • Ingelvac PRRS MLV Indications
  • Warnings and cautions for Ingelvac PRRS MLV
  • Direction and dosage information for Ingelvac PRRS MLV

Ingelvac PRRS MLV

This treatment applies to the following species:
Company: Boehringer Ingelheim

Porcine Reproductive and Respiratory Syndrome Vaccine

Reproductive & Respiratory Forms, Modified Live Virus

This product is manufactured by Boehringer Ingelheim Vetmedica, Inc. Call Customer Service toll free at 1-800-325-9167 with any questions.

For new or additional information on the latest in PRRS virus research and to answer any questions on Ingelvac PRRS® MLV, contact Boehringer Ingelheim Professional Services toll free at 1-800-325-9167.

Ingelvac PRRS MLV Indications

For vaccination of healthy, susceptible swine as an aid in the prevention of respiratory disease and an aid in the reduction of reproductive disease due to Porcine Reproductive and Respiratory Syndrome (PRRS) virus.

Recommended for use in healthy, susceptible swine in PRRS virus positive herds only, per label directions.


Rehydrate only with the diluent provided; do not mix with other materials. Other diluents may be viricidal.

10 dose presentation: Rehydrate the vaccine by adding the full contents of the accompanying liquid diluent to the vaccine vial. Shake well and use immediately.

50 dose and 250 dose presentations: Rehydrate the vaccine by adding a portion of the contents of the accompanying diluent to the vaccine vial. Shake well and transfer the reconstituted suspension back into the diluent bottle. Mix with the remaining diluent to complete the total volume. Shake well and use immediately.


Sows and gilts: Using aseptic technique, inject a single 2 mL dose intramuscularly for the reproductive form of PRRS. Sows and gilts may be vaccinated prior to breeding or at any stage of pregnancy. Vaccination can either be population-targeted as a whole-herd vaccination program where all pregnant and nonpregnant sows and gilts are vaccinated every 3-4 months, or individual animal-targeted by vaccination 3 to 4 weeks prior to each breeding, or as directed by your herd veterinarian. The duration of immunity is at least 4 months or throughout gestation. Piglets: Using aseptic technique, inject a single 2 mL dose intramuscularly to swine 3 weeks of age or older for the respiratory form of PRRS. The duration of immunity is at least 4 months or throughout the finishing period.

Breeding Animals

For use in all swine in PRRS positive herds, except breeding age boars.


For veterinary use only. For use only in swine as directed. Administer only to healthy pigs, gilts, or sows in PRRS virus positive herds, and only by intramuscular injection. Administer the complete 2 mL dose to each pig, gilt, or sow vaccinated. Efficacy and safety of the vaccine at other than the dose or route prescribed on the label is unknown and, therefore, not recommended and not USDA approved. Anaphylactoid reactions may occur. Specific herds may be particularly sensitive. Antidote: Epinephrine.



Storage Before Use

Store out of direct sunlight in the outer carton. Store at a temperature between 35-45°F (2-7°C). Do not freeze. Use entire contents when first opened. Do not use bottles of damaged product. Do not store reconstituted vaccine.

Withdrawal Period

Vaccinated pigs, gilts, or sows are not to be harvested for human consumption before 21 days after vaccination.


After use, burn containers and all unused contents by a procedure allowed by local, state, and Federal regulations.

If human exposure occurs, administer first aid and consult physician immediately.

Many factors must be considered in determining a sound PRRS vaccination program for a particular farm. To be most effective, the vaccine must be administered properly to healthy animals maintained in a proper environment under good management. Stressed or immunosuppressed pigs should not be vaccinated as the efficacy of the vaccine in these animals is unknown. The level of individual animal and herd immunity required will vary with management practices, the degree of exposure to PRRS virus, and the level of susceptibility of each animal. The benefits and risks from vaccination will vary in part with the level of PRRS virus in the herd, and the need for the herd or individual animals to maintain a particular status for virus isolation, serological, or other diagnostic tests. Experience in the field has shown that

Ingelvac PRRS® MLV was most effective in reducing circulating PRRS field virus when used in a whole-herd protocol. The effect of concurrent or previous infections at or around the time of vaccination on the efficacy of this vaccine in reducing or modifying PRRS virus disease in pigs, gilts, and sows is not known. Therefore, the vaccination program must be carefully planned and implemented in collaboration with the herd veterinarian following label and insert indications and precautions.

Shedding of vaccine virus by vaccinates: Vaccine virus may be shed and transmitted to other populations of swine which are in contact with vaccinated swine. The duration of potential vaccine virus transmission may vary.

Research (Gorcyca, et al., unpublished) indicates that vaccine virus is found at varying times post vaccination at locations (tonsil, nasal mucosa, urine, feces) from which the potential for shedding exists. The chances of vaccine virus shedding may be increased when animals are treated with glucocorticoids and possibly by disease or environmental conditions which stress pigs and elevate levels of endogenous glucocorticoids.

One field study (Torrison, 1996) indicated that nonvaccinated pigs in contact with Ingelvac PRRS® MLV vaccinated pigs may seroconvert to vaccine virus. Use of the vaccine on farms or transport of pigs from the farms where vaccine has been used to farms wanting to remain PRRS virus seronegative is contraindicated.

Vaccination during the latter part of gestation of pregnant sows or gilts (Gorcyca, et al., 1995b) which are PRRS virus naive and previously unvaccinated can result in piglets born viremic. The impact of vaccine viremia in the newborn pig is not known.

Vaccination prior to breeding of PRRS negative herds or subpopulations within a positive herd may result in a transient reduction of reproductive performance.

Results of field safety studies following whole-herd vaccination showed the percent of mummies born to primiparous gilts was higher among vaccinates than non-vaccinates at two of three test sites, although there was no apparent difference between vaccinates and nonvaccinates in the number of affected gilts.

Test Site

# gilts/treatment

#gilts having mummies

Average mummies (total grp)

Average mummies (only gilts with mummies)


19 (vaccinates)

4 (21%)



12 (controls)

2 (17%)




31 (vaccinates)

0 (0%)



28 (controls)

0 (0%)




28 (vaccinates)

7 (25%)



27 (controls)

8 (30%)




78 (vaccinates)

11 (14%)



67 (controls)

10 (15%)



Vaccination of adult boars may result in the shedding of vaccine virus in the semen (Molitor et al., 1995; Nielsen et al., 1995; Christopher-Hennings et al., 1995). Because the impact of shedding is not known, do not use in boars of breeding age. This vaccine is not USDA licensed for use in breeding boars.

Reference literature cited is available from Boehringer Ingelheim Vetmedica, Inc.

Boehringer Ingelheim Vetmedica, Inc., St. Joseph, MO 64506

US Vet. Lic. No. 124

US Patent No. 5,846,805


10 Doses

Rehydrate with 20 mL


50 Doses

Rehydrate with 100 mL


250 Doses

Rehydrate with 500 mL


CPN: 1028068.4

Telephone:   800-325-9167
Fax:   816-236-2717
This service and data are provided "AS IS". DVMetrics and assumes no liability, and each user assumes full risk, responsibility, and liability, related to its use of the DVMetrics and services and data. See the terms of use for further details.

Copyright © 2022 Animalytix LLC. Updated: 2021-11-29